Please login to the form below

ribociclib

This page shows the latest ribociclib news and features for those working in and with pharma, biotech and healthcare.

NICE says no to Novartis’ Kisqali combo in breast cancer

Draft guidance from the cost-effectiveness watchdog has concluded CDK 4/6 inhibitor Kisqali (ribociclib) plus fulvestrant should not be offered routinely on the NHS in England for patients with hormone ... More data may address the uncertainties in the

Latest news

NICE gives Lilly’s Verzenios chance to compete with rivals

Novartis’ Kisqali (ribociclib) is far behind Pfizer’s drug (but expected to hit $1.6bn in 2022 according to EvaluatePharma), with Verzenios expected to give Kisquali competition for second place in ... Abemaciclib has been shown to be just as
CHMP backs Sanofi’s all-oral sleeping sickness drug

Among these, Novartis’ CDK4/6 inhibitor Kisqali (ribociclib) was recommended for the treatment of women with hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer in combination with fulvestrant
Novartis claims a rare win at ESMO for PI3K inhibitor class

6 inhibitor, a newer drug group which includes Novartis’ own Kisqali (ribociclib), Pfizer’s Ibrance (palbociclib) and Eli Lilly’s Verzenio (abemaciclib).
Lilly gets EMA nod for Verzenio in breast cancer

46% to $3.1bn last year and is predicted to become a $6bn product at peak by EvaluatePharma - as well as Novartis’ second-to-market CDK4/6 inhibitor Kisqali (ribociclib).
Novartis considers filings for PI3K drug in breast cancer

own Kisqali (ribociclib) and Eli Lilly’s Verzenio (abemaciclib).

More from news
Approximately 4 fully matching, plus 26 partially matching documents found.

Latest appointments

Ipsen boosts specialty care and R&D leadership teams

East. Most recently, Semerjian served as senior vice president and global launch head of ribociclib.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Experienced / Senior Account Director - Publications - London: Up to £80, 000 plus great benefits

Account Director, Medical Education: Salary TBC

Senior Medical Writer: Salary TBC

Home-based Principal Medical Writer – Medical Comms: Salary TBC

Senior Account Director/ Associate Director- Pharma and Life Sci...: Competitive salary and benefits

Hybrid Role - Principal Medical Writer / Account Handler - Publi...: Salary TBC

Science Writer, Healthcare Advertising Agency: £40, 000 - 45, 000 DOE benefits,

Account Manager, Medical Communications and Marketing: £30, 000 – £40, 000 benefits and bonus

Editorial/ Medical Director – Med Ed & Comms – Home-based...: Salary TBC

Senior / Principal Medical Writer - MedComms - Home Based / Vari...: Excellent Remuneration Packages

Editorial / Copy Lead – Healthcare Advertising – Central London...: Salary TBC

Account Director – London based Medical Communications Agency: Excellent Remuneration Package

Senior Medical Writer: Competitive salary and benefits

Project Manager - Medical Communications – South Wales: Excellent Remuneration Package

Account Manager / Senior Account Manager - Healthcare Advertisin...: Excellent Remuneration

Director – Healthcare PR: Salary TBC

Project Manager - Digital Healthcare - London: Excellent Remuneration Package

Account Manager, MedicalCommunications/ Healthcare PR: benefits

PR Associate Director – Consumer Health & Beauty: Salary TBC

Senior Account Manager- Pharma and Life Scienes: Competitive salary and benefits

Freelance Medical Writer - Healthcare Advertising - London: Employment Type:. Type of Job:. Region:. Salary:. 250 to 330 per day

Editor – Medical Education Agency – Bucks: Salary TBC

Subscribe to our email news alerts

PMHub

Add my company

VCCP Health

We’re the challenger agency for challenger brands. Brands with a point to prove. Rx, OTC and wellness brands run by...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality: How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA: Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad: Six behaviours separate the good brand teams from the bad...